PDCD1 and melanoma: To evaluate whether DENR can serve as a potential target or marker in anti-PD1/PD-L1 therapy, we analyzed three independent clinical studies of melanoma patients under anti-PD-139,40, or anti-CTLA-441 treatment regimens (Fig. 7d–f).